Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- ASKA Grants Exclusive Chinese Sales Rights for Altat to Local Firm
January 8, 2021
- LEO Pharma Earns Approval for Dovobet Foam Version
January 7, 2021
- Relugolix Now Available for Advanced Prostate Cancer in US
January 7, 2021
- Mirabegron Gets FDA’s Priority Review for Pediatric NDO: Astellas
January 7, 2021
- Kyowa Kirin Begins Japan PIII for Bardoxolone in ADPKD
January 7, 2021
- Fujifilm to Set Up Viral-Vector Contract Manufacturing Hub in Boston Area
January 6, 2021
- Sosei Regains Global Rights to Muscarinic Agonist Programs from AbbVie, CEO Says It’s Not Bad News
January 6, 2021
- Meiji Pharma Fortifies US Foothold with New Subsidiary
January 6, 2021
- JCR Inks Domestic Production Deal for AstraZeneca COVID-19 Vaccine Solution
January 6, 2021
- Takeda Closes Sales of 16 Non-Core Meds to Germany’s Cheplapharm
January 6, 2021
- Hisamitsu’s Osteoarthritis Patch Drug Enters PIII in US
January 6, 2021
- Kobayashi Kako Corrects Number of Health Damages from Itraconazole Mix-Up
January 6, 2021
- Drug Makers, Wholesalers Brace for Second Emergency Declaration in Japan
January 6, 2021
- Ono, Prof. Honjo Disagree About Validity of Patent Royalty Rate for Opdivo
January 6, 2021
- Daiichi Sankyo Files Sakigake-Designated Oncolytic Virus in Japan After Overcoming Manufacturing Issues
January 6, 2021
- Fuji Pharma Files Natural Progesterone Drug in Japan for Menopausal Disorders
January 5, 2021
- Kobayashi Kako Adds 2 APIs to Class II Recall List, Meiji/Elmed Products
December 28, 2020
- AstraZeneca to Accelerate Growth of Forxiga with Heart Failure Use, Gets Head Start in Arena before Rival Jardiance
December 28, 2020
- US FDA Lifts Clinical Hold for Audentes’ Gene Therapy AT132: Astellas
December 28, 2020
- Opdivo Misses Primary Targets in PIII for Glioblastoma Multiforme: BMS
December 28, 2020
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…